Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.

Clin Cancer Res · 2023 · PMC10618649 · PMID 37756555

Europe PMC DOI

hedged sentences

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

did not reach statistical significanceP = 0.10so close (0.05 < p ≤ 0.1)

27.7 months with placebo; HR 0.39, 95% CI, 0.12–1.26) did not reach statistical significance (log-rank P = 0.10; Fig. 4D ).

also in 111,027 other papers

showed a trendno p-value reported

Among samples with discordant GIScar and MGMC classification, tumors identified as HRD-positive by MGMC but HRD-negative by GIScar showed a trend toward better PFS on olaparib, but in this relatively small subgroup, the difference in mPFS (33.3 months with olaparib vs. 27.7 months with placebo; HR 0.39, 95% CI, 0.12–1.26) did not reach statistical significance (log-rank P = 0.10; Fig. 4D ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.